UTI & Pyelonephritis in Pregnancy
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Separate lower UTI from pyelonephritis and systemic infection. The difference changes the urgency, antibiotic selection and whether outpatient treatment is suitable.
Assessment & interpretation
- Take a midstream urine sample for culture before antibiotics when feasible. Review previous cultures, recent antibiotic exposure, allergies and renal function.
- Fever, flank pain, vomiting or systemic illness requires assessment for upper-tract infection and sepsis.
Decisions that change management
- NICE advises an immediate antibiotic prescription for lower UTI in pregnancy, followed by review of culture and susceptibility results.
- Do not use a lower-UTI medicine as an automatic pyelonephritis regimen. Pregnancy, dehydration, inability to retain oral treatment or severe illness lowers the threshold for specialist or hospital assessment.
- Select treatment using pregnancy safety, infection site and local resistance; narrow therapy when results allow.
Follow-up & safety-netting
- Reassess worsening symptoms immediately, or failure to begin improving within 48 hours of treatment.
- For pyelonephritis treated intravenously, review IV treatment by 48 hours and consider oral step-down only when clinically appropriate.
- Communicate the culture result and any treatment change rather than assuming an empirical prescription completes the pathway.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Suspected pyelonephritis in pregnancy: initial inpatient management (ACOG). Admit sepsis, dehydration, vomiting/inability to take treatment, obstruction concerns or maternal/fetal compromise.
When clinic, day care or home care may be suitable
- Stable lower UTI without fever/flank pain or systemic illness can usually be treated orally with culture-guided follow-up.
Before going home
- Clinical improvement, stable observations, adequate oral intake and a culture-directed treatment plan; investigate persistent fever/pain or failure to improve.
- A suitable oral step-down or supported treatment service is arranged; nitrofurantoin/fosfomycin are not renal-tissue step-down treatment for pyelonephritis.
Discharge medicines and treatment changes
- For pyelonephritis, the selected ACOG regimen completes 14 days total, counting inpatient and outpatient treatment; prescribe the remaining days and a culture-appropriate drug.
- For lower UTI, use the separate complete pregnancy-compatible regimen and avoid restarting a full course at discharge.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
Lower-tract infection only when appropriate; not pyelonephritis step-down.
- Indication: Culture-guided asymptomatic bacteriuria/cystitis; not pyelonephritis
- NICE routine eligibility is eGFR ≥45 mL/min; eGFR 30–44 use is exceptional and needs a specific resistance/benefit-risk assessment.
- Symptoms, culture/susceptibility, renal function and clinical response by 48 hours; stop/review pulmonary or hepatic symptoms
This displayed regimen is for lower UTI; do not use it as a universal upper-UTI prescription.
- Indication: NICE second-choice lower-UTI option when suitable for culture results/allergy history
- Dose adjustment is required with renal impairment. This is not the pyelonephritis step-down prescription for every organism.
- Culture/susceptibility, response within 48 hours, allergy, diarrhoea and renal function
Tests, pending results and their reviewer
- A named clinician reviews culture/susceptibility and contacts the patient if treatment changes. Record the chosen repeat-culture/recurrence plan.
Home care and counselling
- Explain hydration, treatment completion and the difference between bladder symptoms and signs of upper/systemic infection.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
If not improving within 48 hours of treatment | Reassess promptly for resistance, obstruction or another diagnosis. |
At the booked culture/result review | Confirm susceptibility and clinical response; arrange further testing/suppression only when indicated. |
Return urgently
- Fever/rigors, flank pain, vomiting, reduced urine, faintness, worsening illness, contractions or reduced movements needs urgent assessment.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
- Pyelo: admit, IV fluids, antiemetics, CTG surveillance
③ First-line treatment & drug regimens
Distinguish lower UTI/asymptomatic bacteriuria from pyelonephritis before choosing an antibiotic. Use culture results and renal/allergy assessment; fever, loin pain or systemic illness needs the inpatient upper-UTI pathway. The complete cards state the separate courses.
④ Drug treatment detail (3 agents)
- Indication: Culture-guided asymptomatic bacteriuria/cystitis; not pyelonephritis
- NICE routine eligibility is eGFR ≥45 mL/min; eGFR 30–44 use is exceptional and needs a specific resistance/benefit-risk assessment.
- Symptoms, culture/susceptibility, renal function and clinical response by 48 hours; stop/review pulmonary or hepatic symptoms
- Indication: NICE second-choice lower-UTI option when suitable for culture results/allergy history
- Dose adjustment is required with renal impairment. This is not the pyelonephritis step-down prescription for every organism.
- Culture/susceptibility, response within 48 hours, allergy, diarrhoea and renal function
- Indication: Selected inpatient pyelonephritis in pregnancy, guided by cultures and resistance
- The NICE NG111 pregnancy table usually uses cefuroxime; this is the ACOG-compatible ceftriaxone option, not a claim that every guideline chooses the same drug.
- Vitals, sepsis features, renal function, cultures and clinical response within 48–72 h
Monitoring
- Test-of-cure MSU after course
- Recurrent infections: suppression dose discussion + renal US postpartum if recurrent pyelo
⑮ Complications & their management
Preterm labour during pyelo
PTL pathway alongside antibiotics
Post-treatment care
- Hygiene/voiding counselling; low-dose prophylaxis for recurrences per specialist
Diagnosis & assessment
- Haemodynamic instability -> sepsis pathway
Initial assessment
- MSU culture BEFORE therapy
- Temp/loin exam for upper tract
- CTG if viable + contractions
Investigations
| Test | Looking for |
|---|---|
MSU | Organism+sensitivities guide course |
Principles & follow-up
Management principles
Sources (9)
31 October 2018 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for uti-pyelonephritis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/dischar…
31 October 2018 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for uti-pyelonephritis. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/dischar…
· checked 2026-10-17 · verified-live
Open source ↗
Pregnant-patient seven-day nitrofurantoin and cefalexin schedules, modified/immediate-release distinction, renal eligibility, avoid-at-term and upper-UTI exclusions; not the adjacent three-day nonpregnant table.
· checked 2026-10-17 · verified-live
Open source ↗
Inpatient pyelonephritis treatment, culture-directed therapy, 14-day total treatment and inadequate renal-parenchymal coverage from nitrofurantoin/fosfomycin.
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.